Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ: GERN )

1.640 -0.030 (-1.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,617,996
Open 1.680
Bid (Size) 1.630 (7)
Ask (Size) 1.640 (7)
Prev. Close 1.670
Today's Range 1.610 - 1.725
52wk Range 1.460 - 5.340
Shares Outstanding 508,766,846
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron
From Faruqi & Faruqi LLP
Via GlobeNewswire
Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire

Performance

YTD
-54.44%
-54.44%
1 Month
-41.22%
-41.22%
3 Month
-58.16%
-58.16%
6 Month
-63.15%
-63.15%
1 Year
-6.29%
-6.29%

More News

Read More
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS
From Geron Corporation
Via Business Wire
Why Geron Stock Is Plummeting Today
Via The Motley Fool
Earnings Scheduled For February 26, 2025
Via Benzinga
4 Analysts Assess Geron: What You Need To Know
Via Benzinga
Geron Corporation Announces Departure of Chief Executive Officer
From Geron Corporation
Via Business Wire
GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Geron Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's going on in today's session
Via Chartmill
Analyst Scoreboard: 4 Ratings For Geron
Via Benzinga
Dow Dips Over 100 Points; TJX Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Here are the top movers in Wednesday's session.
Via Chartmill
Nasdaq Surges 150 Points; Lowe's Posts Upbeat Earnings
Via Benzinga
Geron (GERN) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Traders are paying attention to the gapping stocks in Wednesday's session.
Via Chartmill
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
Geron to Participate at Upcoming Investor Conferences in March 2025
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
From Geron Corporation
Via Business Wire
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
From Geron Corporation
Via Business Wire
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Geron Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.